Bavarian Nordic A/S (LON:0DPB)

Market Cap	1.36B
Revenue (ttm)	633.85M
Net Income (ttm)	109.55M
Shares Out	n/a
EPS (ttm)	1.40
PE Ratio	12.43
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,393
Average Volume	12,449
Open	153.13
Previous Close	151.40
Day's Range	151.80 - 153.70
52-Week Range	15.94 - 32.81
Beta	1.38
RSI	48.82
Earnings Date	May 9, 2025

About Bavarian Nordic

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV for the treatment of encephalitis viruses. It operates in the Unite...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1992
• Employees: 1,605
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0DPB

Financial Performance

In 2024, Bavarian Nordic's revenue was 5.72 billion, a decrease of -19.06% compared to the previous year's 7.06 billion. Earnings were 987.98 million, a decrease of -33.03%.

Financial numbers in DKK